$2.75
13.19% today
NYSE, Feb 28, 04:54 pm CET
ISIN
US7133171055
Symbol
PEPG
Sector
Industry

PepGen Stock price

$2.43
+0.57 30.65% 1M
-7.14 74.61% 6M
-1.36 35.88% YTD
-12.93 84.18% 1Y
-10.46 81.15% 3Y
-10.46 81.15% 5Y
-10.46 81.15% 10Y
NYSE, Closing price Thu, Feb 27 2025
+0.90 58.82%
ISIN
US7133171055
Symbol
PEPG
Sector
Industry

Key metrics

Market capitalization $79.21m
Enterprise Value $-22.32m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.27
P/B ratio (TTM) P/B ratio 0.67
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-97.74m
Free Cash Flow (TTM) Free Cash Flow $-82.87m
Cash position $120.19m
EPS (TTM) EPS $-2.84
P/E forward negative
Short interest 4.97%
Show more

Is PepGen a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

PepGen Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a PepGen forecast:

4x Buy
80%
1x Sell
20%

Analyst Opinions

5 Analysts have issued a PepGen forecast:

Buy
80%
Sell
20%

Financial data from PepGen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 1.51 1.51
28% 28%
-
-1.51 -1.51
28% 28%
-
- Selling and Administrative Expenses 20 20
28% 28%
-
- Research and Development Expense 75 75
12% 12%
-
-96 -96
15% 15%
-
- Depreciation and Amortization 1.51 1.51
28% 28%
-
EBIT (Operating Income) EBIT -98 -98
15% 15%
-
Net Profit -90 -90
14% 14%
-

In millions USD.

Don't miss a Thing! We will send you all news about PepGen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PepGen Stock News

Neutral
Business Wire
4 days ago
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2024, and recent corporate highlights. “Today, we reported initial results...
Neutral
Business Wire
4 days ago
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 i...
Neutral
Business Wire
30 days ago
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) for patients amenable to an ...
More PepGen News

Company Profile

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Head office United States
CEO James McArthur
Employees 81
Founded 2018
Website pepgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today